Hubungan Ekspresi Sodium Iodide Symporter dengan Varian Histopatologi dan Stadium Papillary Thyroid Carcinoma
Abstract
Abstrak
Tujuan: Mengetahui hubungan ekspresi sodium iodide symporter dengan varian histopatologi dan stadium papillary thyroid carcinoma. Metode: Penelitian ini merupakan penelitian observasional dengan pendekatan cross sectional. Sampel penelitian ini adalah kasus papillary thyroid carcinoma dari laboratorium Patologi Anatomi RSUP Dr. M. Djamil Padang periode Januari 2022-Desember 2022 sebanyak 37 kasus. Varian histopatologi papillary thyroid carcinoma dinilai berdasarkan WHO 2017 dan stadium klinis dinilai berdasarkan TNM American Joint Committee on Cancer edisi ke VIII. Ekspresi NIS dinilai melalui pulasan imunohistokimia. Analisis bivariat dilakukan dengan uji Chi-square dengan hasil uji statistik dianggap bermakna jika p < 0,05. Hasil: Penelitian ini menunjukkan ekspresi NIS positif sebesar 13,5%. Analisis statistik menunjukkan adanya hubungan yang bermakna antara ekspresi NIS dengan varian histopatologi papillary thyroid carcinoma (p=0,03). Varian histopatologi tertentu menunjukkan tingkat ekspresi NIS yang lebih tinggi dibandingkan dengan varian lainnya. Namun, penelitian ini tidak menemukan hubungan antara ekspresi NIS dengan stadium papillary thyroid carcinoma (p =0,61). Kesimpulan: Terdapat hubungan antara ekspresi NIS dengan varian histopatologi. Ekspresi NIS tidak berhubungan dengan stadium papillary thyroid carcinoma.
Kata kunci: sodium iodide symporter; papillary thyroid carcinoma; varian histopatologi; stadium
Keywords
Full Text:
PDFReferences
Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide Increasing Incidence of Thyroid Cancer : Update on Epidemiology and Risk Factors. Journal of Cancer Epidemiology. 2013: 1-11.
Khan A. Surgical Pathology of Endocrine and Neuroendocrine Tumors. Humana Press; 2009:41-80.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71(3):209-249. doi:10.3322/caac.21660
Sun J hung, Li Y rong, Chang K hsuan, Liou M jene. Evaluation of recurrence risk in patients with papillary thyroid cancer through tumor-node- metastasis staging : A single-center observational study in Taiwan. Biomed J. 2021;45(6):923-930.
Rosai J, Albores SJ, Asioli S, Baloch ZW, Bogdanova T, Chen H et al. Papillary thyroid carcinoma in : World Health Organization Classification of Tumours Pathology & Genetics Tumours of Endocrine Organs. Lyon. 2017: 81-85.
Araque KA, Gubbi S, Klubo-gwiezdzinska J, Branch D, Diseases K. Updates on the Management of Thyroid Cancer. Horm Metab Res. 2020;52(8):562-577. doi:10.1055/a-1089-7870.Updates.
Fahey TJ. Updates in the Understanding and Management of Thyroid Cancer.Intechopen.2012:165-188.
Morais RM De, Sobrinho AB, Maria C, et al. Review Article The Role of the NIS ( SLC5A5 ) Gene in Papillary Thyroid Cancer : A Systematic Review. Journal of Cancer Epidemiology.2018:1-11. doi.org/10.1155/2018/9128754
Du L, Zhao Z, Zheng R, Li H, Zhang S, Li R. Epidemiology of Thyroid Cancer : Incidence and Mortality in China. Frontiers in Oncology 2020;10.1-9. doi:10.3389/fonc.2020.01702.
Putri E, Khambri D, R Selvi R. Artikel Penelitian Hubungan Daerah Tempat Tinggal dengan Gambaran Histopatologi Karsinoma Tiroid pada Masyarakat Sumatera Barat. Jurnal Kesehatan Andalas.2014;3(2):147-150.
Hunt L Jennifer . Molecular Pathology of Endocrine Disease. Springer; 2010: 27-36.
Carvalho p denise. ferreira c.f andrea.The Importance of Sodium/Iodide Symporter (NIS) for Thyroid Cancer Management. Arq Bras Endocrinol Metab. 2007;51(5) :672-682.
Ravera S, Reyna-Neyra A, Ferrandino G, Amzel LM, Carrasco N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017;79:261-289. doi:10.1146/annurev-physiol-022516-034125
Elmageed ZYA, Sholl AB, Tsumagari K. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. Surgery.:1-7. doi:10.1016/j.surg.2016.06.081
Griesinta Trianty Andria Pinahayu, Diah Prabawati Retnani KWA, Harun Al Rasyid HS. Hubungan Ekspresi her2 dengan Ukuran Tumor dan Invasi Kapsular PapillaryThyroid Carcinoma ( PTC). Maj Kesehat. 2021;8:20-31.
Humprey Peter A, dehner Louis P, Pleifer John D. the Washington Manual of Surgical Pathology.Wolters Kluwer.; 2012: 404-426.
Rosai J, Talini G. Thyroid gland. In : Rosai and Ackerman’s Surgical Pathology. Tenth Edition. New York. USA. Elsevier. 2011: 487-28.
Glenn D. Braunstein. Thyroid Cancer. 1st ed. Springer Berlin Heidelberg; 2012:133-154
Harahap AS, Subekti I, Panigoro SS, et al. Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital. Appl Clin Genet. 2023:99-110. doi:10.2147/TACG.S412364.
Jalali-Nadoushan MR, Amirtouri R, Davati A, Askari S, Siadati S. Expression of estrogen and progesterone receptors in papillary thyroid carcinoma. Casp J Intern Med. 2016;7(3):183-187.
Bertol BC, Massaro JD, Debortoli G, et al. BRAF, TERT and HLA-G Status in the Papillary Thyroid Carcinoma: A Clinicopathological Association Study. Int J Mol Sci. 2023;24(15). doi:10.3390/ijms241512459.
Morari EC, Marcello MA, Guilhen ACT, et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clinical Endocrinology. 2011:247-254. doi:10.1111/j.1365-2265.2011.04032.x.
Wei S, Gao M, Zhao C. Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma. Int J clin oncol.2013. doi:10.1007/s10147-013-0620-z
Dong H, Shen W zhuang, Yan Y jing, Yi J lin, Zhang L. Effects of BRAF V600E Mutation on Na + / I - Symporter Expression in. J Huazhong univ sci Technol.2016;36(1). doi:10.1007/s11596-016-1545-3.
Tavares C, Tavares C, Coelho MJ, Eloy C, Melo M, Gaspar A. NIS expression in thyroid tumors , relation with prognosis clinicopathological and molecular features. Endocrine connections. 2018;90:78-90.
Zhang H, Chen D. Synergistic inhibition of MEK / ERK and BRAF V600E with PD98059 and PLX4032 induces sodium / iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. Thyroid research .2018:1-6.
Mingzhao Xing. Molecular Pathogenesis of Thyroid cancer. NIH public Access.2013;13(3):184-199. doi:10.1038/nrc3431.Molecular
Lee F, Kuo CY, Tsai CH, Cheng SP. Propensity Score-Matched Analysis to Identify Pathways Associated with Loss of Sodium Iodide Symporter in Papillary Thyroid Cancer. Curr Issues Mol Biol. 2022;44(4):1488-1496. doi:10.3390/cimb44040101.
Almukhtar ZK. Histopathological Types Clinicopathologic Study of Papillary Thyroid Carcinoma. Macedonian Journal of Medical Sciences. 2022;10:79-83.
